Earnings ·
Teleflex reported second quarter 2026 financial results, posting revenue from continuing operations of $570.3 million…
TFXTeleflex Inc
Teleflex reported second quarter 2026 financial results, posting revenue from continuing operations of $570.3 million, up 28.9% year-over-year, and adjusted diluted EPS of $1.76. The company completed the divestiture of its OEM business for approximately $1.5 billion in cash, with estimated after-tax proceeds of $1.25 billion, which were used to pay off a $700 million Term Loan A-2. Teleflex repurchased 1.9 million shares for $250 million during the quarter and announced a new $250 million accelerated share repurchase program effective August 7, 2026. Management reduced full-year 2026 GAAP revenue growth guidance to 13.4%–14.4% and adjusted diluted EPS guidance to $6.90–$7.20, citing slower-than-expected integration of the acquired Vascular Intervention business from BIOTRONIK. The company also received FDA approval for EZPLAZ freeze-dried plasma and advanced clinical trials for its Freesolve magnesium scaffold. Teleflex is a global provider of medical technologies and devices.